Section Review Anti-infectives: New approaches to the treatment of vancomycin-resistant bacterial infections

References to Primary Literature

• PARENT' F, CAVALLERI B: Novel glycopeptide antibiotics of the dalbaheptide group. Drugs Future (1990) 15:57–72.
   Google Scholar
• Glycopeptide Antibiotics. Nagarajan R (Ed.), Marcel Dekker, Inc., New York (1994).
   Google Scholar
• Handbook of Antimicrobial Therapy. Abramowicz R (Ed.), The Medical Letter, Inc., New York (1990).
   Google Scholar
• The choice of antibacterial drugs. Med. Lett. Drugs Ther. (1994) 36:53–60.
   PubMedGoogle Scholar
• SIIABERG DR, CULVER DH, GAYNES RP: Major trends in the microbial etiology of nosocomial infection. Am. J. Med. (1991) 91(Suppl. 3B):72S–75S.
   Google Scholar
• SCIIEEL 0, LYON DJ, ROSDAHL VT, ADEYEMI-DORO FAB, LING TKW, CHENG AFB: In vitro susceptibility of isolates of methicillin-resistant Staphylococcus aureus 1988–1993.j Antimicrob. Chemother. (1996) 37:243–251.
   Google Scholar
• UDO EE, JACOB TE, CHUG H TD: Antimicrobial resistance of coagulase-negative Staphylococci from a Kuwait hos-pital. Microb. Drug Res. (1995) 1:315–320.
   PubMed Web of Science ®Google Scholar
• JANSEN B, SCHUMACHER-PERDREAU F, PULVERER G: Sus-ceptibility of Staphylococci and Enterococci to gly-copeptides, comparison of 3 test methods. Zbl. Bakt. (1995) 282:402–408.
   PubMedGoogle Scholar
• FERRARA A, DOS SANTOS C, CIMBRO M: High-level gen-tamycin-resistant Enterococck in vitro activity of dou-ble and triple combinations of antimicrobial drugs. Chemother. (1996) 42:37–46.
   PubMed Web of Science ®Google Scholar
• WOODFORD N, JOHNSON AP: Glycopeptide resistance in Gram-positive bacteria: from black and white to shades of grey. J Med. Microbiol. (1994) 40:375–378.
   PubMed Web of Science ®Google Scholar
• PLESSIS P, LAMY T, DONNIO PY, AUTULY F, GRULOIS I, LE PRISE' PY, AVAIL JL: Epidemiologic analysis of gly-copeptide-resistant Enterococcus strains in neu-tropenic patients receiving prolonged vancomycin administration. Eur. J. Clin. Microbiol, Infect. Dis. (1995) 14:959–963.
   PubMed Web of Science ®Google Scholar
• GORDTS B, VAN LANDUYT H, IEVEN M, VANDAMME P, GOOSSENS H: Vancomycin-resistant Enterococci colo-nizing the intestinal tracts of hospitalized patients. J. Clin. Micro biol. (1995) 33:2842–2846.
   PubMed Web of Science ®Google Scholar
• HEALTH CII, BLACKMORE TK, GORDON DL: Emerging resistance in Enterococcus spp. Med. J. Aust. (1996)164:116–120.
   PubMed Web of Science ®Google Scholar
• SPELLER DCE, LYNN WA, ROGERS TR: Glycopeptide resistance in Gram-positive bacteria. Clin. Microbiol. Infect.(1995) 1:54–59–
   Google Scholar
• SPERA RV Jr., FARBER BF: Multidrug-resistant Enterococcus faecium. Drugs (1994) 48:678–688.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN KJ, GUBBINS PO: Treatment of vancomychi-resistant Staphylococcal infections. Ann. Pharma-cotber. (1996) 30:288–290.
   Google Scholar
• NOBLE WCZ, V1RANI Z, CREE RGA: Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbtol. Lett. (1992) 93:195–198.
   Web of Science ®Google Scholar
• WOODFORD N, JOHNSON AP, MORRISON D, SPELLER DCE: Current perspectives on glycopeptide resistance. Clin. Micro blot. Rev. (1995) 8:585–615.
   PubMed Web of Science ®Google Scholar
• MALABARBA A, CIABATTI R, SCOTT' R, GOLDSTEIN BP, FERRARI P, ZURZ M, ANDREINI BP, DENARO M: New semisynthetic glycopeptides MDL 63,246 and MDL 63,042, and other amide derivatives of antibiotic A-40,926 active against highly glycopeptide-resistant VanA Enterococci J. Antibiot. (1995) 48:869–883.
   Google Scholar
• LILLY RESEARCH LABS.: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. (1995) AbstractsF242-F251,F254,F255.
   Google Scholar
• NICAS TI: New glycopeptides for vancomycin-resistant Enterococci. Conference on the Frontier of Antibacterial Drug Discovery. Princeton, NJ (1995).
   Google Scholar
• NIARRIOTT MS: LY333328, a new glycopeptide active against vancomycin-resistant enterococci. Exp. Opin. Invest. Drugs (1995) 5:1017–1019.
   Google Scholar
• Glycopeptide antibiotic derivatives active against vancomycin-resistant Gram-positive bacteria. Exp. Opin. Ther. Patents (1996) 6:73–75–
   Google Scholar
• MALABARBA A, CIABATTI R, SCOTT1 R, GOLDSTEIN BP, MARAZZI A, PANZONE GB, DENARO M: MDL 63,246: a new semisynthetic glycopeptide antibiotic active against highly glycopeptide-resistant enterococcL 33rd Interscience Conference on Antimicrobial Agents and Che-motherapy (1993) Abstract 445.
   Google Scholar
• GOLDSTEIN BP, CANDIAN1 G, ARAIN TM, ROMANO' G, CICILIATO I, BERTI M, ABBONDI M, SCOTT' R, MAININI M, RIPAMONTI F, RESCONI A, DENARO M: Antimicrobial activity of MDL 63,246, a new semisynthetic glycopep-tide antibiotic. Antimicrob. Agents Chemother. (1995) 39:1580–1588.
   PubMedGoogle Scholar
• KENNY MT, BRACKMAN MA, DLTLWORTH JK: In vitro activity of the semisynthetic glycopeptide anakle MDL 63,246. Antimicrob. Agents Chemother. (1995) 39:1589–1590.
   PubMed Web of Science ®Google Scholar
• NICAS TI, COLE CT, PRESTON DA, SCHABEL AA, NAGARA- JAN R: Activity of glycopeptides against vancomycin-re-sistant Gram-positive bacteria. Antimicrob. Agents Chemotber. (1989) 33:1477–1481.
   PubMed Web of Science ®Google Scholar
• NICAS TI: Activity of novel semi-synthetic glycopeptides against vancomycin- resistant enterococci. 7th European Congress on Clinical Microbiology and Infectious Diseases. Vienna, Austria (1995).
   Google Scholar
• NICAS TI: Novel semisynthetic glycopeptides active against vancomycin-resistant EnterococcL Program Abstr. Int. Congr. Chemother. Montreal, Canada (1995).
   Google Scholar
• BOYLAN CJ et al.: 35th Interscience Conference on Antimi-crobial Agents and Chemotherapy. (1995) Abstract 255.
   Google Scholar
• BEAUREGARD DA, WILLIAMS DH, GWINN MN, ICNOWLES DJC: Dimerization and membrane anchors in extracel-lular targeting of vancomycin group antibiotics. Antimi-crob. Agents Chemother. (1995) 39:781–785.
   PubMed Web of Science ®Google Scholar
• MALABARBA A, CIABATTI R: Reductive hydrolysis of the 59,60-amide bond of teicoplanin antibiotics: a key step from natural to synthetic glycopeptides. J. Med. Chem. (1994) 37:2988–2990.
   PubMed Web of Science ®Google Scholar
• MALABARBA A, CIABATTI R, KETTENRING J, FERRARI P, VEKEY K, BELLASIO E, DENARO M: Structural modifica-tions of the active site in teicoplanin and related gly-copeptides. 1. Reductive hydrolysis of the 1,2- and 2,3-peptide bonds. J. Org. Chem, (1996) 61:2137–2150.
   Google Scholar
• MALABARBA A, CIABATTI R, MAGGINI M, FERRARI P, COLOMBO L, DENARO M: Structural modifications of theactive site in teicoplanin and related glycopeptides. 2. deglucoteicoplanin-derived tetrapeptide. J. Org. Chem. (1996) 61:2151–2157.
   Google Scholar
• MALABARBA A, CIABATTI R: Synthesis of MDL 63,166. A new chemical approach from natural to synthetic gly-copeptides. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (1995) Abstract F257.
   Google Scholar
• MALABARBA A el al.: Substitution of amino adds 1 and in teicoplanin aglycon: synthesis and antibacterial activity of three first non-natural dalbaheptides. J. An-tibiot. (1996). Submitted.
   Google Scholar
• MIRANDA AG, WAGNER AR, SINGII KV, MURRAY BE: Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resis-tant clinical isolates of Gram-positive cocci. Antimicrob. Agents Chemother, (1992) 36:1325–1328.
   Google Scholar
• Daptomycin (LY-146032). Drugs Future (1991) 16:608–613.
   Google Scholar
• DIXSON S, BRUMF1TT W, HAMILTON-MILLER JMT: In vitro evaluation of ramoplanin (MDL 62198, A 16686). Fur. I Clin. Micro biol. Dis. (1988) 7:819–821.
   Web of Science ®Google Scholar
• LAWRENCE T, ROTSTEIN C, BEAM TR, Jr., GORZYNSKI EA,AMSTERDAM D: In vitro activities of ramoplanin, se-lected glycopeptides, fluoroquinolones, and other an-tibiotics against clinical bloodstream isolates of Gram-positive cocci. Antimicrob. Agents Chemother. (1993) 37:896–900.
   PubMed Web of Science ®Google Scholar
• COLLINS LA, ELIOPOULOS GM, WENNERSTEN CB, FER-RARO MJ, MOEILFRING RC, Jr.: In vitro activity of ra-moplanin against vancomycin- resistant gram-positive organisms. Antimicrob. Agents Chemother. (1993) 37:1364–1366.
   Google Scholar
• LANDMAN D, QUALE JM, BURNEY S, KREISWIRTH B, WILLEY BM: Treatment of experimental endocarditis caused by multidrug resistant Enterococcus faecium with ramoplanin and penicillin. J. Antimicrob. Chemother. (1996) 37:323–329.
   PubMed Web of Science ®Google Scholar
• JOIINSON CC, TAYLOR 5, PITSAKIS P, MAY P, LEVISON ME: Bactericidal activity of ramoplanin against antibiotic-resistant enterococci. Antimicrob. Agents Chemother. (1992) 36:2342–2345.
   PubMed Web of Science ®Google Scholar
• BIAVASCO F, MANSO E, VERALDO PE: In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile. Antimi-crob. Agents Chemother. (1991) 35:195–197.
   PubMed Web of Science ®Google Scholar
• JORDENS JZ, BATES J, GRIFFITHS DT: Faecal carriage and nosocomial spread of vancomycin-resistant Enterococ-cus faecium. J. Antimicrob. Chemother. (1994) 34:515–528.
   PubMed Web of Science ®Google Scholar
• DARCHI PHARM. CO.: 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. (1993) Abstracts 79,80, 975–1004,1188,1189.
   Google Scholar
• AMERICAN CYANAMID CO.: 33rd Interscience Conferenceon Antimicrobial Agents and Chemotherapy. (1993) Abstracts 431–444.
   Google Scholar
• JOHNSON DM, JONES RN: Two investigational glycylgly-cines, DMG-DMDOT and DMG-M1NO. Diagn. Microbiol, Infect. Dis. (1996) 24:33–57.
   Google Scholar
• SCHERING-PLOUGH RES. INST.: 33rd Interscience Confer-ence on Antimicrobial Agents and Chemotherapy. (1993) Abstracts 456–466.
   Google Scholar
• JONES RN, BARRETT MS: Antimicrobial activity of SCH 27899, oligosaccharide member of the everninomycin class with a wide Gram-positive spectrum. Clin. Micro-biol. Infect. (1995) 1:35–43.
   PubMedGoogle Scholar
• JONES RN, JOHNSON DM, ERWIN ME: In vitro antimicro-bial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob. agents Chemother. (1996) 40:720–726.
   PubMed Web of Science ®Google Scholar
• COLLINS LA, MALANOSKI GJ, ELIOPOULOS GM, WENNER-STEN CB, FERRARO MJ, MOELLERING RC, Jr.: In vitro activity of RP59500, an injectable streptogramin antibi-otic against vancomycin-resistant Gram-positive organ-isms. Antimicrob. Agents Chemother. (1993) 37:598–601.
   Google Scholar
• NAKASI ITO S, IWASAWA H, DUN FY, KANEMITSU K, SHI-MADA J: Everninomycin, a new oligosaccharide antibi-otic: its antimicrobial activity, post- antibiotic effect and synergistic bactericidal activity. Drugs Exp. Clin. Res. (1995) 21:7–16.
   PubMedGoogle Scholar
• Upjohn antibiotics show promise. Scrip (1995) 2068:22.
   Google Scholar
• RISTOW TA, NOSKIN GA, WARREN JR, PETERSON LR: In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin- resistant Entero-coccus faecium. Microb. Drug Res. (1995) 4:335–339.
   Google Scholar
• PASCULLE AW, LINDEN PK, McDEVITT DA, WAGENER W, McNIGHT JL, PAPAFRANGAS EA: Susceptibility of van-comycin-resistant Enterococcus faecium (VREF) to al-ternative antimicrobial agents singly and in combination. 33rd Interscience Conference on Antimicro-bial Agents and Chemotherapy (1993) Abstract 1060.
   Google Scholar
• LYNN WA, BALTCH AL, RITZ WJ, SMITH RP: Treatment of CAPD-peritonitis due to glycopeptide-resistant Entero-coccus faecium with quinupristin-daifopristin. Lancet (1994) 344:1025–1026.
   PubMed Web of Science ®Google Scholar
• MILLICHAP J, RISTOW T, BODENER U, NOSKIN G, PETER-SON L.: 35/19 Interscience Conference on Antimicrobial Agents and Chemotherapy (1995) Abstract E120.
   Google Scholar
• RANG SL, RYBAK MJ.: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. (1995) Abstract E121.
   Google Scholar
• GRUPPO LEPETTT SPA., EP-596929 (1995).
   Google Scholar
• ELI LILLY & CO., EP-667353 (1995).
   Google Scholar
• GRUPPO LEPETIT SPA., EP-409045 (1991).
   Google Scholar
• GRUPPO LEPETTT SPA., EP-561827 (1995).
   Google Scholar
• GRUPPO LEPETIT SPA., W09413599 (1994).
   Google Scholar
• ELI LILLY & CO., U54537717 (1985).
   Google Scholar
• GRUPPO LEPETIT S.P.A., GB7912298 (1979).
   Google Scholar
• DALICHI PHARMA. CO., EP-341493 (1989).
   Google Scholar
• AMERICAN CYANAMID CO., EP-582829 (1994).
   Google Scholar
• SCHERING CO., US4597968 (1986).
   Google Scholar
• UPJOHN CO., W09525106 (1995).
   Google Scholar
• AMERICAN CYANAMID CO., US3226436 (1965).
   Google Scholar
• PFIZER, INC., GB901209 (1962).
   Google Scholar